Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVULEN-28 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin oral contraceptive that inhibits ovulation primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and altering cervical mucus and endometrial lining.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy
One tablet (ethinyl estradiol 0.05 mg / ethynodiol diacetate 1 mg) orally once daily for 21 days followed by 7 days placebo; continuous cycle.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); Norethindrone: 5-14 hours (mean ~8 hours). Clinical context: Steady state reached within 5-7 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol is primarily metabolized via CYP3A4; ethynodiol diacetate undergoes extensive first-pass metabolism, converted to norethindrone and other metabolites.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: ~50% as metabolites; Fecal/biliary: ~40% as conjugated metabolites; <1% unchanged in urine.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: 98-99% bound (albumin, SHBG); Norethindrone: 80-85% bound (albumin, SHBG).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 2.3-3.2 L/kg (extensive tissue distribution); Norethindrone: 2.1-2.8 L/kg (distribution consistent with steroid hormones).
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Ethinyl estradiol: 38-48% (extensive first-pass metabolism); Norethindrone: 50-77% (oral bioavailability).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment; use with caution in severe renal impairment.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute or chronic liver disease, including hepatic adenomas or carcinoma; discontinue if jaundice develops.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche; postmenarche: same as adult dosing after assessment of bone age and growth potential.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use after menopause; no specific dose adjustment, but consider increased risk of thromboembolic events and estrogen-dependent neoplasms.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day), particularly in women over 35.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thrombotic disorders (e.g., venous thromboembolism, arterial thromboembolism), cardiovascular events, hepatic neoplasia, and gallbladder disease. Discontinue if jaundice or visual disturbances occur. Monitor for hypertension, depression, and fluid retention.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders; history of deep-vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; hepatic adenoma or carcinoma; active liver disease; hypersensitivity to any component.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No significant food interactions. May be taken with or without food. Grapefruit juice may increase estrogen levels; avoid excessive consumption.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
First trimester exposure is associated with increased risk of noncardiac birth defects (e.g., limb reduction defects) and cardiac anomalies (e.g., VSD, TGA). Postnatal studies show no increased risk with second or third trimester use. Avoid use in pregnancy due to known risks.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in breast milk in low amounts; M/P ratio ~0.3. No adverse effects reported in breastfed infants. Use with caution only if necessary.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No pharmacokinetic data inform dose adjustments; contraindicated in pregnancy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Ovulen-28 (ethynodiol diacetate 1 mg/mestranol 0.1 mg) is a first-generation combined oral contraceptive. Counsel patients to take at the same time daily. If a dose is missed, follow standard missed pill protocol. Drug interactions with rifampin, anticonvulsants, and certain antibiotics may reduce efficacy. Monitor for hypertension, thromboembolism, and liver dysfunction. Not recommended for smokers over 35. Assess for contraindications including history of DVT, stroke, or migraine with aura.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time, even during your period.,If you miss a pill, take it as soon as you remember; if more than 12 hours late, use backup contraception.,Ovulen-28 does not protect against HIV or other STDs.,Common side effects include nausea, breast tenderness, and spotting; these usually improve.,Report symptoms of blood clots (leg pain, chest pain, sudden headache or vision changes) immediately.,Avoid smoking, especially if over 35, due to increased risk of serious side effects.,Tell your doctor about all other medications you take.,Store at room temperature away from moisture and heat.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVULEN-28 vs ALYACEN 7/7/7, answered by our medical review team.
OVULEN-28 is a Oral Contraceptive that works by Combination estrogen-progestin oral contraceptive that inhibits ovulation primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and altering cervical mucus and endometrial lining.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVULEN-28 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVULEN-28 is: One tablet (ethinyl estradiol 0.05 mg / ethynodiol diacetate 1 mg) orally once daily for 21 days followed by 7 days placebo; continuous cycle.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVULEN-28 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVULEN-28 is classified as Category C. First trimester exposure is associated with increased risk of noncardiac birth defects (e.g., limb reduction defects) and cardiac anomalies (e.g., VSD, TGA). Postnatal studies show. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.